Dentists in Winters, CA Accepting Medicare
8 Dentists found. Showing 1 - 8
 Dr. Elizabeth Grover, DDS Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 172 E Grant Ave, Winters, CA 95694 Phone: 530-795-4377 |
 Gene Alan Gowdey, DDS, MA Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 172 E Grant Ave, Winters, CA 95694 Phone: 530-795-4377 Fax: 530-795-3054 |
Dr. Georgina Olazaran Jamison, DDS Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 31 Main St, Winters, CA 95694 Phone: 951-816-7478 |
Dennis Wayne Hiramatsu, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 10 Baker Street, Winters, CA 95694 Phone: 530-795-4137 Fax: 530-795-4137 |
Dr. Adam Patrick Rodriguez, DDS Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 31 Main St, Winters, CA 95694 Phone: 530-795-2157 |
Dr. Ana Maria Antoniu, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 31 Main St, Winters, CA 95694 Phone: 530-795-4377 |
Dr. Ronald Milton Riesner, DDS Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 111 E Grant Ave, Winters, CA 95694 Phone: 530-795-4556 Fax: 530-795-4557 |
Dr. Daniel G Mazza, D.D.S. Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 604 Railroad Ave, Winters, CA 95694 Phone: 530-795-2222 Fax: 530-795-2221 |
News Archive
Positive results from Pearl Therapeutics' Phase 1 study of inhaled combination bronchodilator for COPD
Pearl Therapeutics Inc., a company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from a Phase 1 safety and pharmacokinetics study of PT003, its lead combination therapeutic for the treatment of chronic obstructive pulmonary disease (COPD). Based on these results, and previously announced positive results from Phase 2a studies of PT003's individual components, the company has advanced PT003 into a Phase 2b trial.
Celgene receives FDA approval for POMALYST to treat multiple myeloma
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
New research seeks to address sex disparities in women's health
Traditionally many health-related research projects focused only on males, assuming that females' bodies would respond the same way to a given intervention or drug.
Southern Implants, Keystone announce merger agreement
Keystone Dental, Inc., a leading oral healthcare company dedicated to the delivery of breakthrough implant technology, and Southern Implants, Inc., a producer of unique and innovative dental implant technologies aimed to simplify clinical challenges for implant surgeons and restorative dentists, today announced the companies have merged.
Patients at highly rated hospitals have a 52% lower chance of dying: Study
The largest annual study of patient outcomes at each of the nation's 5,000 nonfederal hospitals found a wide gap in quality between the nation's best hospitals and all others. According to the study, issued today by HealthGrades, the leading independent healthcare ratings organization, patients at highly rated hospitals have a 52 percent lower chance of dying compared with the U.S. hospital average, a quality chasm that has persisted for the last decade even as mortality rates, in general, have declined.
› Verified 1 days ago